Associated Papers
Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation.
Jang DM et al.
Nature Communications, 2025
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.
Spriano F et al.
Haematologica, 2024
The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.
Ryan MB et al.
Cancer Discovery, 2024
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
Pike KG et al.
Journal of Medicinal Chemistry, 2024
An atlas of substrate specificities for the human serine/threonine kinome.
Johnson JL et al.
Nature, 2023
Phosphoproteome Profiling of the Receptor Tyrosine Kinase MuSK Identifies Tyrosine Phosphorylation of Rab GTPases.
Budayeva HG et al.
Molecular & Cellular Proteomics : Mcp, 2022
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Johnson AR et al.
Acs Chemical Biology, 2016
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ et al.
Cancer Discovery, 2013
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
King AJ et al.
Plos One, 2013
Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Kim YK et al.
Cancer Letters, 2012
Active Mek2 as a regulatory scaffold that promotes Pin1 binding to BPGAP1 to suppress BPGAP1-induced acute Erk activation and cell migration.
Pan CQ et al.
Journal of Cell Science, 2010
The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch.
Dhillon AS et al.
Cellular Signalling, 2009
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A et al.
Leukemia, 2009
Raf-1: a novel cardiac troponin T kinase.
Pfleiderer P et al.
Journal of Muscle Research and Cell Motility, 2009
Characterization of Ser338 phosphorylation for Raf-1 activation.
Zang M et al.
The Journal of Biological Chemistry, 2008
A selective cellular screening assay for B-Raf and c-Raf kinases.
Ish T et al.
Journal of Biomolecular Screening, 2007
Regulation of RKIP binding to the N-region of the Raf-1 kinase.
Park S et al.
Febs Letters, 2006
Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5.
von Kriegsheim A et al.
Nature Cell Biology, 2006
Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation.
Trakul N et al.
The Journal of Biological Chemistry, 2005
Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation.
Singh A et al.
Oncogene, 2004
Dynamic changes in C-Raf phosphorylation and 14-3-3 protein binding in response to growth factor stimulation: differential roles of 14-3-3 protein binding sites.
Hekman M et al.
The Journal of Biological Chemistry, 2004
Identification of residues and domains of Raf important for function in vivo and in vitro.
Harding A et al.
The Journal of Biological Chemistry, 2003
Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition.
Tran NH et al.
The Journal of Biological Chemistry, 2003
Phosphorylation of 338SSYY341 regulates specific interaction between Raf-1 and MEK1.
Xiang X et al.
The Journal of Biological Chemistry, 2002
The ankyrin repeat-containing adaptor protein Tvl-1 is a novel substrate and regulator of Raf-1.
Lin JH et al.
The Journal of Biological Chemistry, 1999
Characterization of Raf-1 activation in mitosis.
Laird AD et al.
The Journal of Biological Chemistry, 1999
Autoregulation of the Raf-1 serine/threonine kinase.
Cutler RE et al.
Proceedings of the National Academy of Sciences of the United States of America, 1998
Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
Bosch E et al.
Oncogene, 1997
14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain.
Clark GJ et al.
The Journal of Biological Chemistry, 1997
Activity of plasma membrane-recruited Raf-1 is regulated by Ras via the Raf zinc finger.
Roy S et al.
The Journal of Biological Chemistry, 1997
Mechanisms regulating Raf-1 activity in signal transduction pathways.
Morrison DK
Molecular Reproduction and Development, 1995
Bcr and Raf form a complex in vivo via 14-3-3 proteins.
Braselmann S et al.
The Embo Journal, 1995
Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro.
Dent P et al.
Molecular and Cellular Biology, 1995